Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted) (2019 - 2026)
Akebia Therapeutics (AKBA) reported EPS (Weighted Average and Diluted) of -$0.03 for Q1 2026, down 200.0% year-over-year from $0.03 in Q1 2025, and up 40.0% quarter-over-quarter from -$0.05 in Q4 2025.
Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.03 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.03, down 200.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.08 (up 63.64% YoY), and the FY2025 annual result was -$0.02, up 93.94% from the prior year.
- EPS (Weighted Average and Diluted) climbed to -$0.03 in Q1 2026 per AKBA's latest filing, from -$0.05 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.15 in Q2 2022 and troughed at -$0.35 in Q1 2022.
- A 5-year average of -$0.07 and a median of -$0.05 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) slumped 3458.5% in 2024, then surged 133.33% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.04 in 2022, then soared by 108.19% to $0.0 in 2023, then slumped by 3458.5% to -$0.11 in 2024, then surged by 54.55% to -$0.05 in 2025, then soared by 40.0% to -$0.03 in 2026.
- Business Quant data shows AKBA's EPS (Weighted Average and Diluted) at -$0.03 in Q1 2026, -$0.05 in Q4 2025, and $0.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | -0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.03 |
| Dec 31, 2025 | -0.05 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.03 |
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -0.10 |
| Jun 30, 2024 | -0.04 |
| Mar 31, 2024 | -0.09 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | -0.08 |
| Jun 30, 2023 | -0.06 |
| Mar 31, 2023 | -0.15 |
| Dec 31, 2022 | -0.04 |
| Sep 30, 2022 | -0.29 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | -0.35 |
| Dec 31, 2021 | -0.40 |
| Sep 30, 2021 | -0.34 |
| Jun 30, 2021 | -0.51 |